Comprehensive serial biobanking in advanced NSCLC: Feasibility, challenges and perspectives

Sabine Wessels, Thomas Muley, Petros Christopoulos, Michael Meister, Ingrid Heinzmann-Groth, Arne Warth, Esther Herpel, Simone Hummler, Ursula Klingmüller, Jonas Kuon, Claus Peter Heussel, Ralf Eberhardt, Felix J.F. Herth, Hauke Winter, Helge Bischoff, Albrecht Stenzinger, Martin Reck, Rudolf Maria Huber, Michael Thomas, Marc A. Schneider

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

7 Citaten (Scopus)


Background: Availability of tumor material at baseline and disease progression is increasingly important for patient management in non-small-cell lung cancer (NSCLC), especially for the application of targeted therapies like tyrosine kinase inhibitors and for immune checkpoint inhibitor treatment. Here we report the experience of prospective biomaterial acquisition in advanced NSCLC from a pilot project. Methods: Main objective was the longitudinal collection of high-quality, cryoconserved biopsies in addition to formalin-fixed paraffin-embedded (FFPE) biopsies required for routine diagnostics, along with blood samples and detailed clinical annotation using standardized questionnaires. Results: Over five years, 205 patients were enrolled for the project, yielding 387 cryoconserved biopsies and 1,098 serum, plasma and buffy-coat samples. The feasibility of obtaining the cryoconserved biopsies in addition to the FFPE biopsies was 89% for newly diagnosed cases, but dropped down to 56% and 47% at first and second disease progression, respectively. While forceps biopsy was the preferred procedure for tissue acquisition, the highest tissue amounts were received using the cryobiopsy method. Biopsies had a median tumor cellularity of 34% and yielded in median 13.6 µg DNA and 12 µg RNA (median RIN =8). During the five-year project, a maximum of 38 follow-up blood samples per patient were assembled in up to four therapy lines. Conclusions: Despite the poor condition and limited prognosis of most NSCLC patients, this serial biomaterial acquisition including routine collection of cryoconserved biopsies is feasible to support individualized management. The standardized collection of high-quality material has enabled and enriched several translational research studies that can advance therapeutic options.

Originele taal-2Engels
Pagina's (van-tot)1000-1014
Aantal pagina's15
TijdschriftTranslational Lung Cancer Research
Nummer van het tijdschrift4
StatusGepubliceerd - aug. 2020
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Comprehensive serial biobanking in advanced NSCLC: Feasibility, challenges and perspectives'. Samen vormen ze een unieke vingerafdruk.

Citeer dit